ESMO: European Society for Medical Oncology

The latest news from ESMO

  1. FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients with Locally Advanced Unresectable or Metastatic HER2-positive Gastric Cancer

    Updated indication restricts the use to patients whose tumours express PD-L1 CPS ≥ 1 as determined by an FDA-approved test

  2. ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland

    The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component

  3. A Combination of Osimertinib Plus Pemetrexed and a Platinum-based Agent Significantly Improves PFS in First-Line Treatment of Patients with EGFR-mutated Advanced NSCLC

    Findings from the FLAURA2 study

  4. Efficacy of Rituximab Maintenance in Patients with Mantle Cell Lymphoma Who Are MRD-negative After Induction

    Findings from the European MCL Elderly study

  5. EMA Recommends Extension of Indications for Talazoparib

    New indications concerns a combination with enzalutamide for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated